依托孕烯(Etonogestrel) - 药物靶点：PR_在研适应症：麻醉，避孕_专利_临床

This study aims to evaluate long-term outcomes when the etonogestrel contraceptive implant is inserted at an alternative site located over the scapular. The study will evaluate the pharmacokinetics (i.e., drug levels) and side effect profiles of participants who have an etonogestrel contraceptive implant inserted at this alternative scapular site over the course of at least two years.

开始日期2025-11-01

申办/合作机构

Yale University

CTRI/2024/08/072277

/ Not yet recruitingN/A

A Multi-Center, Open-Label, Randomized, Single Dose, Parallel Design, In Vivo/Ex Vivo Pharmacokinetic study of LSP-9759 (etonogestrel implant, 68 mg) and Nexplanon®, etonogestrel implant, 68 mg in Healthy Female Participants - NIL

开始日期2025-10-01

申办/合作机构

Cliantha Research Ltd.

CTIS2025-520736-41-00

/ Recruiting临床1期

- BLCL-ETN-ANV-01

开始日期2025-06-17

申办/合作机构

Laboratorios Leon Farma SA

100 项与依托孕烯相关的临床结果

登录后查看更多信息

100 项与依托孕烯相关的转化医学

登录后查看更多信息

100 项与依托孕烯相关的专利（医药）

登录后查看更多信息

1,215

项与依托孕烯相关的文献（医药）

2025-10-01·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Evaluation of reference ranges of four circulating sex steroids from dried blood spots in women aged 18-40 years

Article

作者: Desai, Reena ; Davis, Susan R ; Wang, Yuanyuan ; Gialouris, Josh ; Handelsman, David J

Capillary dried blood spot collection offers an excellent less invasive alternative to serum or plasma collection by venesection. This study aimed to generate reference ranges for four sex steroids in capillary whole blood samples collected from healthy premenopausal women as dried blood spots as a screening method to detect disorders of sex development. Using this method we evaluated variations according to age, body mass index, menstrual cycle, and hormonal contraceptive use. This cross-sectional, community-based study included 120 healthy premenopausal women aged 18-40 years, not pregnant or breastfeeding. Whole blood testosterone (T), androstenedione (A4), 17α hydroxyprogesterone (17OHP), and progesterone (P4) were measured by liquid chromatography-tandem mass spectrometry (LCMS) from dried filter paper blood spots. The median (95 % confidence limits) for T were 0.75 (0.28, 2.20) nmol/L, A4 2.69 (1.02, 6.03) nmol/L, 17OHP 1.62 (0.32, 8.52) nmol/L and P4 0.65 (0.18, 41.0) nmol/L. Age by 5-year interval was associated with a progressive reduction in A4 but not for other steroids. Menstrual variation was evident for 17OHP and P4 with increases in luteal phase with a small mid-cycle peak for A4 but no other consistent changes. All sex steroid concentrations were significantly lower in participants taking a systemic hormonal contraceptive (combined oral contraceptive or etonogestrel implant). None of the sex steroid concentrations varied significantly with body mass index. These data provide reference ranges for whole blood T, A4, 17OHP and P4 measured by LCMS from dried blood spots from healthy young adult premenopausal women. Small but significant variations were evident according to age, hormonal contraceptive use and menstrual cycle phase.

2025-10-01·AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Breastfeeding after immediate vs delayed postpartum contraceptive implant placement: a noninferiority randomized controlled trial

Article

作者: Krashin, Jamie W ; Petersen, Timothy R ; Sanchez, Dominique ; Alcantara, Jasmin ; Bulleit, Erin ; Bender, Emily ; Turok, David K ; Espey, Eve ; Leeman, Lawrence ; Black, Patricia ; Trujillo, Victoria Y ; Rivera-Montalvo, Maritza ; Carroll, Smita

BACKGROUND:

Breastfeeding and access to contraception are important to patient and public health. The etonogestrel contraceptive implant is a popular and highly effective long-acting progestin contraceptive with few medical contraindications. Despite theoretical concern about early exogenous progestin exposure inhibiting lactogenesis, previous studies showed reassuring lactogenesis and long-term breastfeeding with immediate placement. However, no studies compare placement within 24 hours postpartum to delayed placement at a postpartum visit.

OBJECTIVE:

We studied the association between etonogestrel contraceptive implant placement within 24 hours vs at least 2 weeks postpartum and breastfeeding continuation at 8 weeks postpartum.

STUDY DESIGN:

We conducted a noninferiority randomized controlled trial of postpartum participants who planned to breastfeed and use the etonogestrel implant at 2 university hospitals in the Mountain West. Participants were at least 13 years old, fluent in English or Spanish, had term deliveries, and lacked contraindications to implant use. They were randomized 1:1 to implant placement within 24 hours or at least 2 weeks postpartum. We collected baseline participant characteristics from chart review and questionnaires. Participants reported breastfeeding status and implant use via electronic questionnaires at 2, 4, 8, 12, and 24 weeks postpartum. The study was powered to assess a 15% noninferiority margin between groups of the primary outcome, any breastfeeding at 8 weeks in the per protocol population.

RESULTS:

We enrolled 150 participants (n=78 immediate, n=72 delayed). After removing participants who declined implant placement, withdrew, or were ineligible (n=8) or lacked primary outcome data (n=16), the modified intention-to-treat analysis included 126 participants (n=69 immediate, n=57 delayed). The per protocol analysis included 115 participants (n=62 immediate, n=53 delayed) after excluding additional participants who received the implant outside of the placement timing windows (n=11). Participants were similar in age, race, and ethnicity, as well as previous breastfeeding experience, delivery mode, and epidural use; the delayed group reported prior implant use less frequently (29% vs 43%). In the per protocol analysis, 77.4% (48/62) of participants in the immediate group and 81.1% (43/53) in the delayed group reported any breastfeeding at 8 weeks; the lower limit of the one-sided 95% confidence interval around this -3.7% difference was -16%, exceeding our predefined noninferiority margin. The difference between groups in the modified intention-to-treat group was smaller (-0.6%) and within the noninferiority margin (-12.8% lower limit of the 1-sided 95% confidence interval): 78.3% (54/69) immediate and 78.9% (45/57) delayed. Implant continuation at 24 weeks trended toward favoring immediate placement (96%, 52/54) compared to in those assigned to delayed placement, (85%, 39/46, P=.08). Exclusive or any breastfeeding and implant continuation through 24 weeks were similar between groups.

CONCLUSION:

The results demonstrated no clinically important differences in breastfeeding and implant continuation outcomes though our primary outcome exceeded our predefined noninferiority margin. These reassuring data add to the evidence base for supporting etonogestrel implant initiation for breastfeeding people whenever they desire it postpartum.

2025-10-01·CONTRACEPTION

Retraction notice to “A pilot efficacy study with a single-rod contraceptive implant (Implanon®1) in 200 Indonesian women treated for ≤ 4 years” [Contraception 59/3 (1999) 167–174]

Article

作者: Korver, Tjeerd ; Paul Geurts, T B ; Coelingh Bennink, Herjan J T ; Affandi, Biran

40

项与依托孕烯相关的新闻（医药）

2025-09-11

·米内网

【关注】透视半年报，读懂上海医药的增长韧性与活力

精彩内容截至8月31日，上市公司半年报披露完毕，A股共5432家上市公司披露2025年半年度报告。公开资料显示，我国上市公司产业结构持续优化，内生动能基础稳步夯实，科技发展主线愈发鲜明，新质生产力加速培育成长，高质量发展取得积极成效。据了解，近六成公司营收正增长，超四分之三公司实现盈利。以医药行业为例，头部企业盈利优势显著，政策与创新双轮驱动下，创新驱动全链增长。8月29日，上海医药发布的2025半年报就用科技叙事验证了这一观察。纵观今年上半年医药企业半年报，不仅创新药板块迎来标志性转折点，多家上市药企发布的半年报显示，创新药业务已成为其业绩增长的核心驱动力，部分公司创新药收入占比已突破50%甚至更高。而在商业板块，上海医药以及国药控股、华润医药、九州通等头部医药商业交出一份惊艳的“答卷”，A股上市公司半年报显示，上半年我国医药工业制造业业绩稳健、流通板块释放出新潜能，成长韧性强劲。工业转型持续推进，产学研深度融合构建生态竞争力通过分析上海医药上半年的财报便能管中窥豹。从财务数据来看，2025年上半年上海医药营业收入为1415.93亿元，同比增长1.56%；其中，医药工业板块取得营收121.60亿元。医药商业营收1294.33亿元，同比增长2.17%。净利润方面，上海医药上半年归母净利润为44.59亿元，同比增长51.56%。具体来看，工业板块贡献利润11.50亿元，主要参股企业贡献利润3.38亿元，商业板块贡献利润17.94亿元。分析这份靓丽的利润成绩单，除获得和黄药业会计核算由合营企业权益法核算变更为按子公司核算而产生的一次性特殊权益外，工业板块的积极转型和商业板块的创新升级为企业的高质量发展注入了全新动能。而工业板块，创新驱动成为其高质量发展的主引擎。最新财务数据显示，在研发投入方面，上海医药研发创新稳步迈进，上半年研发投入11.48亿元，研发费用达9.59亿元，占医药工业销售收入9.44%。据行业现有数据统计，2025年上半年创新药企业平均研发投入比例约为25~28%，这一研发投入比例超过行业的平均水平。在不断发展进步的研发创新体系下，截至报告期末，上海医药新药管线共计56项，其中创新药管线44项，改良型新药管线12项。报告期内，多款重点新药获得新进展。上海医药自主研发的新一代化药一类药品口服非肽类小分子肾素抑制剂I001片（SPH3127）高血压适应症NDA上市申请已获得受理并完成注册检验与注册核查。全球创新型抗CD20抗体药物B001（静脉注射液）/B007（皮下注射液）取得新进展，B007重症肌无力适应症Ⅱ期临床试验以及天疱疮适应症Ⅱ期临床试验均已完成全部受试者入组。化药1类创新药SHPL-49注射液拟用于治疗急性缺血性脑卒中（AIS）的Ⅱ期临床试验已经完成，公开资料显示其具多靶点、多通路的神经保护作用机制。同样值得关注的是，在中药新药研发方面，中药1.1类新药参芪麝蓉丸拟用于治疗轻、中度脊髓型颈椎病（气虚血瘀肾亏证）的Ⅲ期临床试验正有序推进。无独有偶，另一款中药1.1类新药藿苓生肌颗粒（SRD4610）拟用于治疗肌萎缩侧索硬化症（ALS）的Ⅲ期临床试验也正式启动，同时其在美的pre-IND申请也已获得FDA受理。 2025年上半年，上海医药在自研体系优化上聚焦免疫、精神神经、肿瘤、心血管、消化、抗感染六大疾病领域。在大分子早研、小分子多肽、PROTAC、转化评价等多个技术平台取得阶段性进展。全重实验室在新靶标、新机制原创候选药发现上获新突破，6个项目完成立项。同时，上海医药还在积极推进原料药、制剂、生化、抗感染技术研究所的建设。此外，在开源创新生态上，依托上海生物医药前沿产业创新中心（上海前沿）与上海交通大学医学院共建“前沿新药技术概念验证中心”，报告期内完成泌码、慧合谷等8家高成长性企业入驻，打造覆盖科技成果“早期发现-概念验证-技术转移”全链条，强化产学研深度融合。通过对头部企业的观察，创新力为业绩长虹垫高了竞争门槛。据悉，我国目前拥有1775种first-in-class（首创新药）管线，全球占比为19%；从license-out（技术授权出海）数量来看，全球占比为14%，总金额全球占比达30%，中国医药正逐渐成为全球医药创新的重要源头。商业创新升级，CSO业务实现战略性突破如果说创新药逐步进入收获期，对工业板块而言如虎添翼，那么商业板块的转型则可以看做是上药新征程的锦上添花，今年上半年，上海医药在医药分销赛道的表现有目共睹，以1294.33亿元收入展现不俗实力。业内观点分析认为，上海医药在分销领域构建起的现代化供应链服务能力的提升是其业绩增长的关键驱动力，目前覆盖全国25个省份、直辖市与自治区的商业渠道以及零售网络，可持续为各级医疗机构、零售机构、合作伙伴及患者等提供高效、便捷、可靠的服务。 2025年医药流通行业‌市场规模超3万亿元‌，同比增长约4%，这一增长主要得益于医药工业的稳定发展，但同时受医保、集采政策深化的影响使得增速趋缓。其中释放出的信号有以下几点：其一，‌行业集中度提升‌，在“两票制”“集中带量采购”等政策推动下，市场向国药控股、上海医药、华润医药等龙头企业集中，中小流通企业面临整合压力。其二，随着智能仓储、区块链溯源、AI需求预测等技术的广泛应用，医药电商推动O2O模式普及，医药流通领域的‌数字化转型加速，企业更加注重“降本增效”。其三，日趋严格的‌监管环境使得‌合规成本上升，GSP认证、飞行检查等提高行业门槛，部分中小企业生存面临困难。 2025年上半年，上海医药表现出“工业提质、商业稳增”的高质量发展底色。结合财报得以洞察，上海医药的核心优势在于工商研投一体化优势，加之丰富的产品结构与强大的商业网络和完善的供应链服务体系。报告期内，上海医药医药商业板块以科技创新与数智化引领发展，保持良好增长态势。在商业合作方面，合约销售（CSO）业务实现战略性突破，合作产品数量与服务规模持续增长，2025年4月与欧加隆合作，在全国医院渠道内为利维爱、欣妈富隆、依伴侬等产品提供营销服务；同月与益普生围绕达菲林产品达成战略合作；2025年6月获得博安生物GLP-1类降糖药度拉糖肽注射液中国大陆独家推广与总经销权。此外，进口总代业务充分发挥全球供应链优势。新增进口总代品规25个，实现销售收入175亿元，同比增长11.7%；创新药业务与安斯泰来、康方生物、乐普生物、科迪药业、中外制药等多家创新药企达成战略合作，实现销售收入242亿元，同比增长22.6%；器械大健康业务引进5个新产品，实现销售收入225.7亿元；医美业务实现销售收入14亿元，同比增长18.8%。在新零售领域，上海医药发布“上药新零售一体化战略”，依托旗下零售网络与成熟供应链体系，深化批零协同，以上药云健康、华氏大药房、上药院边药房、镁信健康四大业务板块为核心，构建“以患者为中心”的专业一体化、一站式、闭环式新零售体系，提升服务价值与患者体验。透过上海医药的年中报，行业的共性清晰显现：带量采购、国谈降价与医院端议价等多重因素加压，使价格下行与费用刚性并行，分销毛利见底大趋势难以逆转，规模也将不再自动转化为利润。从这些头部企业的特质来看，医药行业的竞争呈现出的态势是组织能力与资金使用效率成为企业的硬实力呈现，及时找准“第二增长曲线”更显企业洞察力，不断注入创新活力与创新生态优势才得以在当下“薄利”的时代中站稳脚跟。只有不断提升核心竞争力，才能在医药产业发展浪潮中持续前行。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

财报

2025-08-12

·ETPharma

With Implanon in 16 States, Organon Doubles Down on Women’s Health Access in India

New Delhi: Global healthcare company Organon is doubling down on its Asia-Pacific strategy, with India emerging as a key growth market on the back of rising contraceptive access , new partnerships, and steady momentum in long-acting reversible birth control. In an interview with ETPharma, Andreas Daugaard Jørgensen, Managing Director – Asia Pacific at Organon, said the company is gaining ground in Asia despite headwinds in other therapeutic areas. A pivotal part of the strategy is the company’s hormonal implant, Implanon NXT , which has been added to India’s national family planning program in a pilot phase. Implanon NXT, a subdermal single-rod contraceptive implant, is steadily gaining traction in India as part of the government’s push to expand the basket of long-acting reversible contraceptive (LARC) options. Available in both the public and private sectors, it forms part of India’s FP2030 commitment to diversify contraceptive choices under the National Family Planning Program. Positioned as a modern, highly effective alternative, the implant is suitable for delaying a first pregnancy, spacing births, or limiting family size. Its non-uterine design and rapid return to fertility make it particularly appealing to young women. The method has found acceptance among women in both urban and rural settings, with demand continuing to grow. “We’re seeing good growth across the region, especially in India,” Jørgensen said. “The rollout of Implanon into public programs marks a critical step in expanding women’s access to reversible contraception.” Introduced into public facilities in September 2023, Implanon NXT has since seen its footprint expand significantly. In 2024, the government extended the program to seven additional states, taking the total to 16—Rajasthan, Gujarat, Karnataka, Bihar, West Bengal, Tamil Nadu, Odisha, Assam, Delhi, Madhya Pradesh, Meghalaya, Chandigarh, Goa, Jharkhand, Chhattisgarh, and Maharashtra. Jørgensen said Implanon is currently the company’s most important product in the region. “Unintended pregnancies remain a significant public health challenge,” he said. “Long-acting reversible methods are getting more attention, especially as countries grapple with both high fertility in some populations and under-replacement fertility in others.” Organon, which spun out of Merck in 2021, now employs around 100 full-time staff in India and between 400 and 500 contract workers, according to Jørgensen. The company is also involved in partnerships with the Gates Foundation, WHO, and other organizations aimed at improving women’s health access and education through digital platforms. “Getting the right information into the hands of both providers and women is critical,” he said. Pipeline pivot One of the company’s most anticipated pipeline assets—OG-6219, for endometriosis —was shelved earlier this year after failing in Phase 2 trials. But Jørgensen said the setback hasn’t changed Organon’s broader R&D focus. “We remain fully committed to endometriosis and other conditions uniquely or disproportionately affecting women,” he said, pointing to other additions to the portfolio, including a migraine therapy marketed in partnership with Eli Lilly and a non-steroidal dermatology product aimed at pregnant women and children. “Endometriosis remains massively underdiagnosed and underserved,” he added. “The trial didn’t work, but the need hasn’t changed.” Biosimilar footprint Organon recently acquired TOFIDENCE, a tocilizumab biosimilar, in the U.S. and continues to evaluate other opportunities. “Globally, biosimilars will continue to be a growth driver,” Jørgensen said, pointing to upcoming loss of exclusivity on large biologics over the next five years. “We’re cautious about where we launch,” Jørgensen said. “It depends on whether the health system is ready and the commercial conditions are viable.” Organon, still a relatively young company, is also working on paying down debt accumulated after its spinout. But Jørgensen said the company’s mission is clear: to fill gaps in healthcare for women. As part of its global Her Promise initiative, Organon aims to prevent more than 100 million unintended pregnancies by 2030, in collaboration with governments and non-profit organizations. By Rashmi Mabiyan ,

并购临床2期

2025-08-12

·ETPharma

With Implanon in 16 States, Organon Doubles Down on Women’s Health Access in India

New Delhi: Global healthcare company Organon is doubling down on its Asia-Pacific strategy, with India emerging as a key growth market on the back of rising contraceptive access , new partnerships, and steady momentum in long-acting reversible birth control. In an interview with ETPharma, Andreas Daugaard Jørgensen, Managing Director – Asia Pacific at Organon, said the company is gaining ground in Asia despite headwinds in other therapeutic areas. A pivotal part of the strategy is the company’s hormonal implant, Implanon NXT , which has been added to India’s national family planning program in a pilot phase. Implanon NXT, a subdermal single-rod contraceptive implant, is steadily gaining traction in India as part of the government’s push to expand the basket of long-acting reversible contraceptive (LARC) options. Available in both the public and private sectors, it forms part of India’s FP2030 commitment to diversify contraceptive choices under the National Family Planning Program. Positioned as a modern, highly effective alternative, the implant is suitable for delaying a first pregnancy, spacing births, or limiting family size. Its non-uterine design and rapid return to fertility make it particularly appealing to young women. The method has found acceptance among women in both urban and rural settings, with demand continuing to grow. “We’re seeing good growth across the region, especially in India,” Jørgensen said. “The rollout of Implanon into public programs marks a critical step in expanding women’s access to reversible contraception.” Introduced into public facilities in September 2023, Implanon NXT has since seen its footprint expand significantly. In 2024, the government extended the program to seven additional states, taking the total to 16—Rajasthan, Gujarat, Karnataka, Bihar, West Bengal, Tamil Nadu, Odisha, Assam, Delhi, Madhya Pradesh, Meghalaya, Chandigarh, Goa, Jharkhand, Chhattisgarh, and Maharashtra. Jørgensen said Implanon is currently the company’s most important product in the region. “Unintended pregnancies remain a significant public health challenge,” he said. “Long-acting reversible methods are getting more attention, especially as countries grapple with both high fertility in some populations and under-replacement fertility in others.” Organon, which spun out of Merck in 2021, now employs around 100 full-time staff in India and between 400 and 500 contract workers, according to Jørgensen. The company is also involved in partnerships with the Gates Foundation, WHO, and other organizations aimed at improving women’s health access and education through digital platforms. “Getting the right information into the hands of both providers and women is critical,” he said. Pipeline pivot One of the company’s most anticipated pipeline assets—OG-6219, for endometriosis —was shelved earlier this year after failing in Phase 2 trials. But Jørgensen said the setback hasn’t changed Organon’s broader R&D focus. “We remain fully committed to endometriosis and other conditions uniquely or disproportionately affecting women,” he said, pointing to other additions to the portfolio, including a migraine therapy marketed in partnership with Eli Lilly and a non-steroidal dermatology product aimed at pregnant women and children. “Endometriosis remains massively underdiagnosed and underserved,” he added. “The trial didn’t work, but the need hasn’t changed.” Biosimilar footprint Organon recently acquired TOFIDENCE, a tocilizumab biosimilar, in the U.S. and continues to evaluate other opportunities. “Globally, biosimilars will continue to be a growth driver,” Jørgensen said, pointing to upcoming loss of exclusivity on large biologics over the next five years. “We’re cautious about where we launch,” Jørgensen said. “It depends on whether the health system is ready and the commercial conditions are viable.” Organon, still a relatively young company, is also working on paying down debt accumulated after its spinout. But Jørgensen said the company’s mission is clear: to fill gaps in healthcare for women. As part of its global Her Promise initiative, Organon aims to prevent more than 100 million unintended pregnancies by 2030, in collaboration with governments and non-profit organizations. By Rashmi Mabiyan ,

并购临床2期

100 项与依托孕烯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04104	依托孕烯	G03AC08	DB00294

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	加拿大	Merck Canada, Inc.	2020-07-15
避孕	美国	Organon USA LLC	2006-07-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痛经	临床2期	-	Merck Sharp & Dohme Corp.	2013-01-21
原发性痛经	临床2期	-	Organon & Co.	2013-01-21
出血	临床2期	-	Organon & Co.	2009-11-01
下尿路症状	临床2期	-	Organon & Co.	2008-03-01
前列腺增生症	临床2期	-	Merck Sharp & Dohme Corp.	2008-03-01
前列腺增生症	临床2期	-	Organon & Co.	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04669678 (EPIC, CTgov)	临床4期	药物相互作用 \| HIV感染 \| 避孕	110	Etonogestrel (Group 1 DOR + ETG)	壓鹹襯遞獵鹽淵淵願襯(襯鬱齋夢製積鏇襯鹽襯) = 憲遞製夢選選壓選願選壓蓋觸繭鹽鏇觸蓋鹽顧 (壓鬱積製構願鬱夢獵夢, 鹹獵憲鹽襯繭壓窪餘夢 ~ 網鹹鹽衊獵觸願淵鹽選) 更多	-	2025-04-08
				Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (Group 2 DOR + IM DMPA)	壓鹹襯遞獵鹽淵淵願襯(襯鬱齋夢製積鏇襯鹽襯) = 願範淵糧鑰構襯鏇夢壓壓蓋觸繭鹽鏇觸蓋鹽顧 (壓鬱積製構願鬱夢獵夢, 鬱衊顧餘願鏇壓鬱壓壓 ~ 鹽選繭鏇觸鏇廠遞糧醖) 更多
NCT03282799 (CTgov)	临床2期	获得性免疫缺陷综合征 \| 避孕	72	etonogestrel implant (Standard Dose Etonogestrel Implant)	顧淵鏇窪餘構遞願繭積 = 鏇獵製餘醖選製構鹹觸顧顧獵製遞鑰齋鏇餘鑰 (齋醖鬱網製襯遞糧鏇顧, 網膚繭顧築觸艱繭鏇憲 ~ 鑰壓淵簾衊築餘窪觸獵) 更多	-	2024-09-05
				etonogestrel implant (Increased Dose Etonogestrel Implant)	顧淵鏇窪餘構遞願繭積 = 鏇構構網蓋窪膚鏇膚製顧顧獵製遞鑰齋鏇餘鑰 (齋醖鬱網製襯遞糧鏇顧, 齋壓獵製糧襯築廠蓋廠 ~ 糧製繭糧顧遞淵膚壓齋) 更多
NCT03282799 (Pubmed \| Am J Obstet Gynecol)	临床2期	药物相互作用	-	Double Etonogestrel Implant	遞築遞壓顧艱夢窪廠遞(築願範製網廠鹹壓廠鹽) = 獵餘築夢淵憲淵遞夢壓艱淵糧廠夢夢鬱鏇夢襯 (顧襯壓廠淵糧鑰顧窪簾 )	-	2024-08-01
				Single Etonogestrel Implant	遞築遞壓顧艱夢窪廠遞(築願範製網廠鹹壓廠鹽) = 艱鏇鏇繭膚網憲願觸製艱淵糧廠夢夢鬱鏇夢襯 (顧襯壓廠淵糧鑰顧窪簾 )
NCT04678817 (Pubmed \| Contraception) 人工标引	N/A	避孕	153	Oral levonorgestrelwith same-day etonogestrel implant	範鑰窪衊構壓遞糧觸顧(積構築鏇廠醖鏇齋襯鑰) = 糧廠構襯積艱鹽醖鏇艱蓋糧製鬱襯築遞構積艱 (餘壓鑰艱選蓋衊製衊構, 0.23 ~ 5.19) 更多	积极	2023-11-25
NCT04463693 (CTgov)	临床4期	避孕	5	Etonogestrel	製築選顧簾艱範蓋鹹鏇(鏇膚糧網壓蓋膚壓蓋鏇) = 鏇鑰餘齋鹽淵觸夢觸願襯衊繭網構餘糧齋憲構 (蓋糧餘憲壓鬱範衊選網, 168.2) 更多	-	2023-06-08
NCT02866643 (LADII, CTgov)	临床3期	避孕	95	Etonogestrel-Immediate (Delivery Room Insertion)	廠艱選鬱鹹夢簾製憲鏇(構壓積艱簾願餘鹽獵齋) = 構襯製餘顧鏇糧築繭範鏇繭鏇願窪鏇衊製鹹繭 (網獵鏇壓餘簾夢淵壓遞, 25.1) 更多	-	2020-09-29
				Etonogestrel (Postpartum Insertion)	廠艱選鬱鹹夢簾製憲鏇(構壓積艱簾願餘鹽獵齋) = 夢夢糧觸夢窪鑰憲餘夢鏇繭鏇願窪鏇衊製鹹繭 (網獵鏇壓餘簾夢淵壓遞, 35.8) 更多
NCT03585504 (Implanon, CTgov)	临床3期	避孕行为	81	Etonogestrel contraceptive implant (Intervention Group)	顧艱襯夢餘壓衊鹽壓艱 = 淵構獵顧鹹網觸網膚觸網糧築壓觸鏇鹽鑰積鹹 (齋壓醖淵鬱鬱獵衊糧鏇, 鹽糧積觸遞簾鬱醖糧衊 ~ 襯鹹憲膚鏇鏇鹽餘壓獵) 更多	-	2018-10-04
				Etonogestrel contraceptive implant (Control Group)	顧艱襯夢餘壓衊鹽壓艱 = 餘鏇窪範蓋遞鹹獵糧壓網糧築壓觸鏇鹽鑰積鹹 (齋壓醖淵鬱鬱獵衊糧鏇, 積繭顧襯壓衊觸夢壓選 ~ 膚憲積鏇餘蓋糧鹹網窪) 更多
ISRCTN33378571 (Pubmed \| Contraception)	N/A	-	-	Etonogestrel-releasing contraceptive implant	窪鹽選網窪網顧構淵願(積鬱襯窪壓獵壓醖積願) = 願獵壓餘鹽構襯簾簾餘構壓窪積齋構壓鹹憲醖 (鑰鬱願構蓋衊簾製衊膚, 2.5 ~ 3.5)	-	2018-09-01
				Levonorgestrel-releasing contraceptive implant	窪鹽選網窪網顧構淵願(積鬱襯窪壓獵壓醖積願) = 憲製餘製製蓋壓餘夢糧構壓窪積齋構壓鹹憲醖 (鑰鬱願構蓋衊簾製衊膚, 2.4 ~ 3.4)
NCT01299116 (LARC, CTgov)	临床4期	避孕	916	oral contraceptives+DMPA (Preference SARC)	衊壓構憲範遞糧憲艱夢 = 網繭網構窪顧構鹹夢壓夢選壓夢構遞糧願顧齋 (遞憲製淵鑰夢選遞築製, 鹽選選鬱鹽憲鹽鹹鬱夢 ~ 醖鹹獵鹹繭醖製衊觸遞) 更多	-	2018-01-26
				ParaGard®+Mirena®+Implanon® (Randomized LARC)	衊壓構憲範遞糧憲艱夢 = 製醖繭繭窪繭憲淵鹹壓夢選壓夢構遞糧願顧齋 (遞憲製淵鑰夢選遞築製, 觸淵顧窪構齋蓋廠簾構 ~ 築顧鏇願鑰積壓齋膚選) 更多
NCT00828542 (CTgov)	N/A	母乳喂养 \| 避孕	40	etonogestrel implant	淵齋製繭構壓鏇觸選壓(壓夢蓋淵鏇遞襯遞鑰蓋) = 膚鹽築襯鹽網構顧願網鑰壓廠鑰艱夢夢襯壓淵 (鹽網鏇獵鏇壓積襯網簾, 1.8) 更多	-	2017-05-15